Jazz Pharmaceuticals plc
http://jazzpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jazz Pharmaceuticals plc
Jazz’s Suvecaltamide Fails In Tremor Trial, But Parkinson’s Study Continues
A Phase IIb trial evaluating suvecaltamide failed to show a statistically significant benefit versus placebo on an assessment scale for essential tremor.
Leftfield Obesity Mechanism Hurts Shionogi
When it comes to weight loss drug development, the sensible move is to follow the pack.
Jazz’s CNS Pipeline Demonstrates Transformation
With a first-in-class cannabis-derived treatment for epilepsy, a market-leading treatment for sleep disorders and now a foray into movement disorders, Jazz’s CNS pipeline is strong.
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
Company Information
- Industry
- Biotechnology
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice